MRKR · Marker Therapeutics
The AI's read
A share-price rise does not explain what changed in Marker Therapeutics' business. The article gives no company update, so it offers no new reason to change the company's outlook.
Marker Therapeutics shares rose 21.2% to $1.11, but the article gives no business news behind the move. It does not change the company's outlook.
A share-price rise does not explain what changed in Marker Therapeutics' business. The article gives no company update, so it offers no new reason to change the company's outlook.
Cryo-Cell International shares rose 15.89% to $4.23, but the article gives no business news behind the move. It does not change the company's outlook.
Alaunos Therapeutics shares rose 16.56% to $2.54, but the article gives no business news behind the move. It does not change the company's outlook.
CytoSorbents shares rose 14.37% to $3.50, but the article gives no business news behind the move. It does not change the company's outlook.
Actuate Therapeutics shares rose 12.3% to $0.56, but the article gives no business news behind the move. It does not change the company's outlook.
ALX Oncology Holdings shares rose 11% to $1.11, but the article gives no business news behind the move. It does not change the company's outlook.
Follow Marker Therapeutics (MRKR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRKR